Document Detail


Aminoacyl-tRNA synthetase inhibitors as antimicrobial agents: a patent review from 2006 till present.
MedLine Citation:
PMID:  23062029     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Aminoacyl-tRNA synthetases (aaRSs) are one of the leading targets for development of antimicrobial agents. Although these enzymes are well conserved among prokaryotes, significant divergence has occurred between prokaryotic and eukaryotic aaRSs, which can be exploited in the discovery of broad-spectrum antibacterial agents. Although several aaRS inhibitors have been reported before, they failed as a result of poor selectivity and limited cell penetration.
AREAS COVERED: This review covers January 2006 to April 2012 wherein several new analogues were claimed as aaRS inhibitors. Anacor Pharmaceuticals patented several boron-containing derivatives inhibiting the function of the editing domain of aaRSs. Two patents describe the combination of aaRS inhibitors with other antibacterial agents. Patents disclosing aaRS inhibitors for indications other than antimicrobial agents are not considered for review here.
EXPERT OPINION: Several recently disclosed leads may form the foundation for development of potent and selective bacterial aaRS inhibitors. In comparison with, for example, terbinafine and itraconazole, compound C10 (AN2690) is a very promising candidate for treatment of ungual and periungual infections with improved nail penetration and low keratin binding. In addition, Raplidyne, Inc. reported bicyclic heteroaromatic compounds as potent and selective inhibitors of bacterial MetRS. These have proven to be particularly effective for treatment of Clostridium difficile-associated diarrhea. Finally, combination of aaRS inhibitors to attenuate resistance looks as a viable strategy to expand the lifespan of existing antibiotics.
Authors:
Bharat Gadakh; Arthur Van Aerschot
Related Documents :
15866179 - Mechanism of aurora b activation by incenp and inhibition by hesperadin.
8845369 - Kinetic mechanisms of the forward and reverse pp60c-src tyrosine kinase reactions.
21937289 - Hb riesa or β93 (f9) cys→ser, a new electrophoretically silent haemoglobin variant inte...
21213249 - Measuring rapid hydrogen exchange in the homodimeric 36 kda hiv-1 integrase catalytic c...
12161559 - Transplanting allosteric control of enzyme activity by protein-protein interactions: co...
9070439 - Importance of the a-helix of the catalytic subunit of camp-dependent protein kinase for...
10747999 - Isohemoglobin differentiation in the bimodal-breathing amazon catfish hoplosternum litt...
4027219 - Nanosecond optical spectra of iron-cobalt hybrid hemoglobins: geminate recombination, c...
25393949 - Borrelidin b: isolation, biological activity, and implications for nitrile biosynthesis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2012-10-12
Journal Detail:
Title:  Expert opinion on therapeutic patents     Volume:  22     ISSN:  1744-7674     ISO Abbreviation:  Expert Opin Ther Pat     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-20     Completed Date:  2013-05-10     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9516419     Medline TA:  Expert Opin Ther Pat     Country:  England    
Other Details:
Languages:  eng     Pagination:  1453-65     Citation Subset:  IM    
Affiliation:
KU Leuven, Rega Institute for Medical Research, Laboratory of Medicinal Chemistry, Minderbroedersstraat 10, 3000 Leuven, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acyl-tRNA Synthetases / antagonists & inhibitors*,  metabolism
Animals
Anti-Bacterial Agents / chemistry,  pharmacology*,  therapeutic use
Bacteria / drug effects*,  enzymology,  growth & development
Bacterial Infections / drug therapy,  microbiology
Drug Design*
Enzyme Inhibitors / chemistry,  pharmacology*,  therapeutic use
Humans
Molecular Structure
Patents as Topic*
Protein Conformation
Structure-Activity Relationship
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Enzyme Inhibitors; EC 6.1.1.-/Amino Acyl-tRNA Synthetases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Coaches' interpersonal style, basic psychological needs and the well- and ill-being of young soccer ...
Next Document:  Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric ca...